Comparison
of Two Different Regimens of Combined Interferon Alfa- 2a (Pegasys) and Lamivudine
Therapy in Children with Chronic Hepatitis B
In
the current study, investigators evaluated the efficacy of two regimens of combined
interferon
alfa-2a (IFN alfa-2a) [Pegasys] and lamivudine (3TC) [Epivir-HBV] therapy
in children with chronic hepatitis B. A
total of 177 patients received IFN alfa-2a, 9 million units (MU)/m2 for 6 months.
In group I (112 patients), 3TC (4 mg/kg/day, max 100 mg) was started simultaneously
with IFN alfa-2a. In group II (65 patients) 3TC was started 2 months prior to
IFNalfa-2a. 3TC
was continued for 6 months after antiHBe seroconversion
or stopped at 24 months in nonresponders.
In
conclusion, the authors write, "Simultaneous 3TC+IFN alfa-2a yields a higher
response and earlier antiHBe seroconversion and viral clearance than consecutive
combined therapy. Relapse rate is low." "Predictors
of response are high basal ALT and high HAI scores."
"3TC can
be administered for 24 months without any side effect and breakthrough rate is
comparable with previous studies." 05/12/06 Reference
A
Kansu, T Doganci, S A Akman, and others. Comparison of two different regimens
of combined interferon-alfa2a and lamivudine therapy in children with chronic
hepatitis B infection. Antiviral Therapy 11(2): 255-261. 2006.
|
Baseline alanine aminotransferase (ALT) was 134.2 ±34.1 and 147.0 ±45.3;
histological activity index (HAI) was 7.4 ±2.7 and 7.1 ±2.3; and
HBV DNA levels were above 2,000 pg/ml in 76% and 66% of patients in groups I and
II, respectively (P>0.005). 
